A 24-Week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo and Tresiba in Insulin-Naive Patients with Type 2 Diabetes Mellitus Not Adequately Controlled with Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Trial Profile

A 24-Week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo and Tresiba in Insulin-Naive Patients with Type 2 Diabetes Mellitus Not Adequately Controlled with Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin degludec
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2017 Planned End Date changed from 1 Oct 2017 to 18 Aug 2017.
    • 15 Jun 2017 Planned primary completion date changed from 1 Oct 2017 to 18 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top